Form 4: United Therapeutics Insider Trades Common Stock

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the acquisition and disposition of common stock on June 25, 2026, under a Rule 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO and Director of United Therapeutics Corp, engaged in a series of transactions on June 25, 2026.
• These transactions included the acquisition of 9,500 shares of common stock at a price of $135.42 per share.
• Concurrently, Rothblatt disposed of a total of 5,000 shares of common stock through multiple sales at prices ranging from $543.12 to $555.31.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• The plan is set to continue until the earlier of the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026.
• Following these transactions, Rothblatt's beneficial ownership of common stock is detailed across direct holdings and indirect holdings through trusts and a spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it details routine insider transactions under a pre-established plan, with both acquisitions and dispositions occurring, balancing potential positive and negative interpretations.

Positives

• The acquisition of 9,500 shares at $135.42 per share indicates continued investment in the company by a key executive.
• The execution of transactions under a Rule 10b5-1 plan suggests a structured and pre-determined approach to managing equity, potentially mitigating insider trading concerns.

Negatives

• The disposition of 5,000 shares of common stock at significantly higher prices than the acquisition price could be interpreted as a profit-taking action by a key executive.
• The weighted average sale price of approximately $543.54 to $555.31 per share indicates a substantial value realized from the disposed shares.

Risks

• The Rule 10b5-1 plan has an expiration date of December 31, 2026, or upon the exercise of a large number of stock options, introducing a potential timeline for future significant transactions.
• The plan's continuation is also tied to the exercise of stock options, which could lead to further sales of common stock if exercised.

Future Outlook

The Rule 10b5-1 trading plan is active and will continue until December 31, 2026, or until 1,734,410 stock options are exercised, whichever comes first. This suggests potential for further stock transactions by the reporting person within this timeframe.

Management Comments

• The exercise of stock options and sale of resulting shares were pursuant to a pre-arranged 10b5-1 trading plan.
• The plan will continue until the earlier of the exercise of 1,734,410 stock options, all of which expire on March 15, 2027, or December 31, 2026.
• Transactions were executed in multiple trades at various prices, with the reported price reflecting the weighted average.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The use of a Rule 10b5-1 plan by a CEO is common practice to diversify holdings or manage personal finances in a way that complies with insider trading regulations, especially in the biopharmaceutical sector where stock-based compensation is prevalent.

Stakeholder Impact

• Shareholders may view the acquisition of shares positively, indicating executive confidence, while the sale of shares could be seen as profit-taking.
• Employees may observe these transactions as part of standard executive compensation and equity management practices.

Next Steps

• The Rule 10b5-1 trading plan will continue until December 31, 2026, or until 1,734,410 stock options are exercised.
• Further transactions may be reported on subsequent Form 4 filings as dictated by the trading plan.

Key Dates

Keywords

Form 4, Insider Trading, Stock Options, Rule 10b5-1, Beneficial Ownership, United Therapeutics Corp, UTHR, Common Stock, Securities Exchange Act, SEC Filing